Abstract
Recently, single-nucleotide polymorphisms near the IL28B gene have been identified as important in predicting treatment response and spontaneous clearance of the hepatitis C virus (HCV). In the less than 12 months since the initial genetic discoveries, our knowledge base has rapidly expanded regarding the significance of the IL28B polymorphism in a variety of clinical settings. For genotype 1 HCV infection, it is clear that IL28B genotype has an important role in the prediction of treatment-induced and spontaneous clearance. This association remains important in the HIV/HCV-coinfected population. Host genotype adds further discriminatory information in HCV genotype 2/3 infection. IL28B genotype may remain significant with direct-acting antiviral therapy, although further studies are needed for antiviral agents and novel immunotherapy. Information on IL28B genotype improves treatment prediction with standard of care and will integrate with existing pretreatment clinical factors and measures of on-treatment response. Pretreatment knowledge of sustained viral response may help to reshape treatment regimens of the future with the possibility of reducing therapy duration and improving tolerability, safety, and efficacy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. Aug 6, 2009;361(6):580–593.
Muir AJ, Bornstein JD, Killenberg PG, the Atlantic Coast Hepatitis Treatment Group. Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites. N Engl J Med. May 27, 2004, 2004;350(22):2265–2271.
Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470–477.
Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. Sep 2005;43(3):425–433.
Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44(1):97–103.
Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C. Annals of Internal Medicine. March 2, 2004 2004;140(5):346–355.
Mangia A, Andriulli A. Tailoring the length of antiviral treatment for hepatitis C. Gut. January 1, 2010 2010;59(01):1–5.
Manuel R-G, Maria Del Mar V, Raúl JA, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636–641.
Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43(6):1177–1186.
Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis. N Engl J Med. December 7, 2000 2000;343(23):1673–1680.
Harrison SA, Elizabeth MB, Rizwan AQ, et al. Effect of Significant Histologic Steatosis or Steatohepatitis on Response to Antiviral Therapy in Patients with Chronic Hepatitis C. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2005;3(6):604–609.
Martínez-Bauer E, Crespo J, Romero-Gómez M, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology. 2006;43(1):72–80.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49(4):1335–1374.
Berg T, von Wagner M, Nasser S, et al. Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology. 2006;130(4):1086–1097.
Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response. Gastroenterology. 2010;138(2):503–512.e501.
Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. Gastroenterology. 2006;131(2):451–460.
•• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. Sep 17 2009;461(7262):399–401. First and largest GWAS to look at treatment response in HCV in a cohort that was uniformly well characterized from the IDEAL trial, and the only GWAS to include African Americans. Identified IL28B polymorphism as top SNP.
•• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. Oct 2009;41(10):1105–1109. GWAS on-treatment response in Japanese population identifying IL28B polymorphism as top SNP.
•• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. Oct 2009;41(10):1100–1104. GWAS on an Australian-European cohort identifying IL28B polymorphism as top SNP.
•• Rauch A, Kutalik Z, Descombes P, et al. Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology. 2010;138(4):1338–1345.e1337. First GWAS to assess spontaneous clearance. This study also included subgroups of HIV/HCV-coinfected patients, HCV genotype 2/3, and treated patients as top SNP.
McCarthy JJ, Li JH, Thompson A, et al. Replicated Association Between an Interleukin-28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology. In press, uncorrected proof.
Halfon P, Bourlière M, Ouzan D, et al. 1167 IL-28 gene variation predicts who will respond to interferon-based treatment of chronic hepatitis C in a French cohort. Journal of Hepatology. 2010;52(Supplement 1):S451–S451.
Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clinical Gastroenterology and Hepatology. In Press, Accepted Manuscript.
• O’Brien T, Bonkovsky H, Pfeiffer R, et al. 1174 Association of IL28B genotype with virological response to pegylated-interferon plus ribavirin in patients with advanced chronic hepatitis C enrolled in the HALT-C trial. Journal of Hepatology. 2010;52(Supplement 1):S454–S454. IL28B polymorphism is significant in the setting of advanced liver disease.
•• Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–129.e118. This paper assessed all patients from the IDEAL trial irrespective of adherence and begins the process of integrating IL28B into response-guided therapy algorithms.
Howell CD, Thompson AJ, Ryan K, et al. 1168 IL28B genetic variation associated with early viral kinetics and SVR in HCV genotype 1: the VIRAHEP-C study. Journal of Hepatology. 2010;52(Supplement 1):S451–S451.
• Neumann A, S. Bibert, B. Haagmans, A. Soulier, F. Negro, M. Lagging, C. Ferrari, S. Zeuzem, J.-M. Pawlotsky, S. Schalm, P.-Y. Bochud, DITTO-HCV group. IL28B Polymorphism is significantly correlated with IFN anti-viral effectiveness already on first day of pegylated interferon-a and ribavrin therapy of chronic HCV infection. 45th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria. 2010:Poster 2011. Demonstrates impact of IL28B polymorphism on viral kinetics affecting predominantly first-phase decline more than second phase.
•• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. Oct 8 2009;461(7265):798–801. First study to assess spontaneous clearance using a candidate gene approach.
Tillmann HL, Thompson AJ, Patel K, et al. A Polymorphism Near IL28B Is Associated With Spontaneous Clearance of Acute Hepatitis C Virus and Jaundice. Gastroenterology. 2010;In Press, Uncorrected Proof.
• Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010:n/a–n/a. This study follows an acute HCV infection cohort and provides an indication of how IL28B may be used in this setting to guide management.
Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250–256.
• Mangia A, Thompson AJ, Santoro R, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology.In Press, Uncorrected Proof. This is the first paper to look specifically at non-1 HCV genotypes and IL28B polymorphism.
•• Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24(8):F23–F29 10.1097/QAD.1090b1013e3283391d3283396d. This is the first paper to look specifically at HIV/HCV coinfection.
Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. Jan 2003;4(1):63–68.
Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. Jan 2003;4(1):69–77.
Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. Oct 2006;44(4):896–906.
Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. Dec 2006;131(6):1887–1898.
•• Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences. May 13, 2008 2008;105(19):7034–7039. This study correlates increased ISG expression to poorer treatment outcome.
•• Chen L, Borozan I, Feld J, et al. Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral Infection. Gastroenterology. 2005;128(5):1437–1444. This study correlates increased ISG expression to poorer treatment outcome.
•• Honda M, Sakai A, Yamashita T, et al. Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C. Gastroenterology. 2010;139(2):499–509. This paper was the first to correlate ISG expression to IL28B genotype and outcome.
• Urban TJ, Thompson AJ, Bradrick SS, et al.: IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in chronic hepatitis C patients. Hepatology. 2010 in press. This study correlates ISG expression to IL28B genotype and outcome, using in vitro models with putative functional variants to assess IL28B potency.
• Shebl FM, Maeder D, Shao Y, Prokunina-Olsen L, Schadt EE, O’Brien TR. In the Absence of HCV Infection, Interferon Stimulated Gene Expression in Liver is Not Associated With IL28B Genotype. Gastroenterology. In Press, Uncorrected Proof. This study demonstrates that IL28B affects ISG expression only with active HCV infection.
Evans JP, Dale DC, Fomous C. Preparing for a Consumer-Driven Genomic Age. New England Journal of Medicine. 2010;363(12):1099–1103.
Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43(5):954–960.
Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010:n/a–n/a.
Shiffman ML, Suter F, Bacon BR, et al. Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3. New England Journal of Medicine. 2007;357(2):124–134.
•• Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52(2):421–429. This is the first paper to assess the significance of IL28B polymorphism with direct-acting antiviral therapy.
Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;9999(9999):NA.
Thompson AJ, Muir AJ, Sulkowski MS, et al. Hepatitis C trials that combine investigational agents with pegylated-interferon should be stratified by IL28B genotype. Hepatology. 2010:n/a–n/a.
Acknowledgments
The authors thank Reinhold Muller for comments on an early draft. P. Clark and A. Thompson received funding support from the Duke Clinical Research Institute, the Richard B. Boebel Family Fund, and the Gastroenterology Society of Australia. A. Thompson received funding from the National Health and Medical Research Council of Australia and the Royal Australasian College of Physicians.
Disclosure
Conflicts of interest: P. Clark—none; A. Thompson—coinventor of a patent application based on the IL28B finding; A. Muir—research grants from Abbott, Anadys, Gilead, Glaxo SmithKline, Idera, Medtronic, Merck, Pfizer, Pharmasset, Roche, Scynexis, Santaris, Three Rivers Pharma, Vertex, and Zymogenetics, and consulting services for Bristol-Myers Squibb, Merck, Pharmasset, Salix, Santaris, Vertex, and Zymogenetics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clark, P.J., Thompson, A.J.V. & Muir, A.J. IL28B Polymorphisms and Treatment of Hepatitis C. Curr Hepatitis Rep 10, 70–78 (2011). https://doi.org/10.1007/s11901-010-0061-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11901-010-0061-3